ROIV Nasdaq

Roivant Sciences Ltd.

ROIV | $10.935 3.16% 3.06% 5M

(0.0% 1d) (6.5% 1m) (19.5% 1y) (0.0% 2d) (0.0% 3d) (1.5% 7d) (14.14% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 8,811,926,076
http://roivant.com/
Sec Filling | Patents | 2021 employees

(BM) Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies

add to watch list Paper trade email alert is off

Press-releases

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Published: 2024-04-02 (Crawled : 11:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 1.63% | O: 4.79% H: 3.02% C: -0.09%
pharma million authorization positive repurchase results study

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| -9.48% | O: 1.2% H: 0.34% C: -3.46%
ABUS | $2.74 3.79% 3.65% 1.1M

Health Technology

| -9.28% | O: -1.37% H: 0.0% C: -2.44%
year update financial results

Global Dermatological Drugs Market Set to Surpass US$30 Billion with Advanced Nanotechnology and Aging Population Fostering Growth
Published: 2024-02-28 (Crawled : 11:00) - prnewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| -10.17% | O: -0.76% H: 0.51% C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M

Health Technology

| -8.12% | O: 0.05% H: 0.06% C: -0.95%
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -6.81% | O: 0.67% H: 0.0% C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M

Health Technology

| -6.09% | O: 0.6% H: 0.02% C: -1.03%
global set dermatological advanced growth market

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| -2.48% | O: 0.0% H: 1.38% C: -0.64%
business update financial results

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 3.72% | O: 0.78% H: 0.97% C: -2.91%
report business update financial results

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 6.43% | O: 4.52% H: 2.02% C: 1.25%
IMVT S | $28.65 -0.31% -0.31% 1.1M

Health Technology

| -20.56% | O: 11.69% H: 0.64% C: -3.24%
disease positive results

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
Published: 2023-12-14 (Crawled : 14:30) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| -1.94% | O: 2.22% H: 1.27% C: 0.72%
rvt-3101 disease antibody treatment acquisition roche

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 16.48% | O: -0.11% H: 0.66% C: 0.0%
IMVT S | $28.65 -0.31% -0.31% 1.1M

Health Technology

| -14.31% | O: 2.92% H: 6.63% C: 4.32%
imvt-1402 positive potential results

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 16.1% | O: -3.29% H: 3.34% C: 3.06%
lupus results study phase 2

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 20.32% | O: -1.93% H: 5.79% C: 4.75%
business update financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001140361-24-021495	4	2024-04-24	2024-04-20	Sell	F	10945	1153706
0001140361-24-021494	4	2024-04-24	2024-04-20	Sell	F	8515	258697
0001140361-24-021493	4	2024-04-24	2024-04-20	Sell	F	9881	177888
0001140361-24-021492	4	2024-04-24	2024-04-20	Sell	F	16002	484200